Business Wire

NY-BORN

2.3.2021 15:14:05 CET | Business Wire | Press release

Share
BORN Expands With Alkeon B2B Market Network Platform Transforming Commercial Models, Starting With the Trade Show Industry

BORN, announces the expansion of innovative B2B subsidiary Alkeon, the world's first global SaaS market-network combining content, community, and commerce to connect buyers and sellers through a best-in-class platform, powered by machine learning. The 2020 pandemic generated a tremendous and immediate need for companies of all categories to pivot at a moment’s notice, with over 10,000 global trade shows completely upended due to cancellations of physical events. BORN, a purpose driven lifestyle company dedicated to reimagining the discovery, transaction and connection of the B2B and B2C communities, found an opportune moment to quickly scale and enhance their technology solutions. The company formally established Alkeon, an enterprise dedicated to supporting the needs of companies who are adapting to the current and future landscapes and need the right partner to support them through the process.

Combining aesthetic and function to create designed technology, Alkeon is a market-network company that enables brands to create an always-on commercial model, digitally optimize their existing infrastructure, capture detailed audience insights and more. Starting with the immediate needs of the global trade show market, Alkeon represents over 15,000 buyers and 150,000 new products by the end of the year. The B2B solution has seen hyper growth and solidified contracts from some of the most influential global trade shows including Tranoï (part of GL Events), Cosmoprof, Brand Assembly, Reassemble, Esxence and Bridal Harrogate.

Founder and CEO of BORN, Jean-Christophe states, “We have seen gaps in the B2B and B2C supply chains for several years, with many aspects of both still operating with analogue systems that lack the benefits of full digital capabilities, audience intelligence and ways to expand and enhance traditional commercial models. The last year has made these gaps stark, leaving many companies in a position to innovate quickly in order to survive. The trade show audience was not only deeply disrupted, but is crucial for global commerce. The tech solutions that we’ve developed have implications for several industries, but we chose to focus on this important category that supports economies around the world. Longterm, businesses, including trade shows, will need a hybrid model that combines the best of technology with the great benefits of physical interaction. We’re creating the solutions for now and well into the future.”

Alkeon’s technology platform empowers trade shows to digitally transform their business, and expand their business internationally with buyers, agents, showrooms and distributors. Brands using BORN's Alkeon service can select a package that ranges from $99 a month to $15,000 a year with various offerings, including intelligent matchmaking, a suite of connection tools such as in-app messaging and video meetings, actionable insights about their business such as buyer engagement and trending product reports. Alkeon offers buyers best-in-class product discovery experience powered by machine learning, delivering personalized product recommendations, curated product lists, and the ability to save products.

“Early on, we asked ourselves the question, “Why can’t B2B be beautiful?”. So we set out with the goal to delight wholesale buyers with a refined, feature-rich product discovery and purchase experience typically reserved for direct-consumer experiences.” - Brendan Wypich, Chief Design & Product Officer.

The platform provides a sleek interface for each brand to present their story and products so that buyers can make quick and informed business decisions. Alkeon streamlines a brand’s workflows by providing full transparency and clear tracking of buyer order flows from initial interest through to purchase order all while staying in constant contact with the buyer. The result is a simplified wholesale buying process that future-proofs the brand’s operations while scaling their business footprint.

BORN began developing the Alkeon technology well before the pandemic hit. Alkeon offers a pleasing and educational discovery experience along with a seamless infrastructure. With quick expansion, BORN and Alkeon will chart the course for the future of retail and wholesale, using the best of the latest technology to learn and adapt, curate and personalize and allow for broader market access. The benefits of the technology have game-changing implications for tradeshows, showrooms, brands, media companies, press agents and buyers.

About BORN:

BORN specializes in digital, data-led solutions to digitize retail supply chains and reimagine discovery and transaction online. BORN owns Alkeon, a suite of B2B solutions and software products that digitize tradeshows and showrooms, as well as Born.com, a platform connecting thousands of luxury design-led brands with premium retailers. BORN is led by CEO Jean-Christophe Chopin, ex-founder of E*Trade EU and Verisign EU.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme

Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release

Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release

On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-

Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release

Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac

The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release

The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye